Vertex Pharmaceuticals (VRTX) Gains from Investment Securities (2009 - 2026)

Vertex Pharmaceuticals' Gains from Investment Securities history runs 18 years deep, the most recent figure standing at $5.0 million for Q1 2026.

• In Q1 2026, Gains from Investment Securities fell 5.66% year-over-year to $5.0 million; the TTM figure through Mar 2026 stood at $1.6 billion (up 21067.57% YoY), while the FY2025 annual figure was $1.6 billion, up 4562.8% from the prior year.
• Gains from Investment Securities was $5.0 million for Q1 2026 at Vertex Pharmaceuticals, down from $389.4 million in the prior quarter.
• In the past five years, Gains from Investment Securities ranged from a high of $1.2 billion in Q3 2025 to a low of -$874.2 million in Q4 2023.
• Historically, Gains from Investment Securities has averaged $103.6 million across 5 years, with a median of $4.3 million in 2025.
• The sharpest annual moves came in 2022 and 2025: Gains from Investment Securities sank 3175.0% in 2022, then jumped 389133.33% in 2025.
• A 5-year view of Gains from Investment Securities shows it stood at $982.7 million in 2022, then plunged by 188.96% to -$874.2 million in 2023, then soared by 100.15% to $1.3 million in 2024, then soared by 29853.85% to $389.4 million in 2025, then plunged by 98.72% to $5.0 million in 2026.
• The last three Gains from Investment Securities figures came in at $5.0 million (Q1 2026), $389.4 million (Q4 2025), and $1.2 billion (Q3 2025), per Business Quant data.